Oleoylethanolamide Exhibits GPR119-Dependent Inhibition of Osteoclast Function and GPR119-Independent Promotion of Osteoclast Apoptosis.


Journal

Molecules and cells
ISSN: 0219-1032
Titre abrégé: Mol Cells
Pays: Korea (South)
ID NLM: 9610936

Informations de publication

Date de publication:
30 Apr 2020
Historique:
received: 06 11 2019
revised: 09 12 2019
accepted: 10 12 2019
pubmed: 14 2 2020
medline: 15 12 2020
entrez: 14 2 2020
Statut: ppublish

Résumé

Oleoylethanolamide (OEA), a bioactive lipid in bone, is known as an endogenous ligand for G protein-coupled receptor 119 (GPR119). Here, we explored the effects of OEA on osteoclast differentiation, function, and survival. While OEA inhibits osteoclast resorptive function by disrupting actin cytoskeleton, it does not affect receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast differentiation. OEA attenuates osteoclast spreading, blocks actin ring formation, and eventually impairs bone resorption. Mechanistically, OEA inhibits Rac activation in response to macrophage colony-stimulating factor (M-CSF), but not RANKL. Furthermore, the OEA-mediated cytoskeletal disorganization is abrogated by GPR119 knockdown using small hairpin RNA (shRNA), indicating that GPR119 is pivotal for osteoclast cytoskeletal organization. In addition, OEA induces apoptosis in both control and GPR119 shRNAtransduced osteoclasts, suggesting that GPR119 is not required for osteoclast apoptosis. Collectively, our findings reveal that OEA has inhibitory effects on osteoclast function and survival of mature osteoclasts via GPR119-dependent and GPR119-independent pathways, respectively.

Identifiants

pubmed: 32050752
pii: molcells.2020.2260
doi: 10.14348/molcells.2020.2260
pmc: PMC7191045
doi:

Substances chimiques

Endocannabinoids 0
Oleic Acids 0
oleoylethanolamide 1HI5J9N8E6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

340-349

Références

Cell Metab. 2006 Mar;3(3):167-75
pubmed: 16517404
Small GTPases. 2011 May;2(3):117-130
pubmed: 21776413
EMBO J. 2003 Dec 15;22(24):6653-64
pubmed: 14657036
J Biol Chem. 2000 Apr 21;275(16):11993-2002
pubmed: 10766830
Small GTPases. 2014;5:e28119
pubmed: 24614674
J Bone Miner Res. 2011 May;26(5):1099-110
pubmed: 21542010
J Cell Physiol. 2019 Feb;234(2):1659-1670
pubmed: 30076703
Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11527-32
pubmed: 25049422
J Cell Physiol. 2019 Jul;234(7):11490-11499
pubmed: 30478996
Calcif Tissue Int. 2011 Jan;88(1):75-86
pubmed: 21110188
Nat Med. 2005 Jul;11(7):774-9
pubmed: 15908955
J Leukoc Biol. 2014 Feb;95(2):337-45
pubmed: 24130113
Nature. 2003 May 15;423(6937):337-42
pubmed: 12748652
Nature. 1999 Jan 28;397(6717):315-23
pubmed: 9950424
Diabetes. 2009 May;58(5):1058-66
pubmed: 19208912
J Exp Med. 1997 Dec 15;186(12):2075-80
pubmed: 9396779
J Immunol. 2009 Aug 1;183(3):1804-12
pubmed: 19592646
Nature. 2003 Sep 4;425(6953):90-3
pubmed: 12955147
J Clin Invest. 2010 Jun;120(6):1981-93
pubmed: 20501942
Nat Rev Immunol. 2007 Apr;7(4):292-304
pubmed: 17380158
J Cell Biol. 2007 Mar 12;176(6):877-88
pubmed: 17353363
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16511-6
pubmed: 19805329
J Bone Miner Res. 2000 Aug;15(8):1477-88
pubmed: 10934646
J Bone Miner Res. 2011 Mar;26(3):657-65
pubmed: 20814968
Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17710-5
pubmed: 20876113
Nature. 2001 Nov 8;414(6860):209-12
pubmed: 11700558
J Clin Invest. 2006 Aug;116(8):2152-60
pubmed: 16878176
Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):696-701
pubmed: 16407142
J Cell Sci. 2010 Sep 1;123(Pt 17):2955-63
pubmed: 20720152
Bone. 2009 Mar;44(3):476-84
pubmed: 19059369
J Cell Physiol. 2016 Apr;231(4):844-51
pubmed: 26280807
J Clin Invest. 2000 Feb;105(4):433-40
pubmed: 10683372
Cell. 1998 Apr 17;93(2):165-76
pubmed: 9568710
Cell Metab. 2009 Aug;10(2):139-47
pubmed: 19656492
Mol Pharmacol. 2006 Sep;70(3):786-92
pubmed: 16772520
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597-602
pubmed: 9520411
Science. 2000 Sep 1;289(5484):1504-8
pubmed: 10968780
Diabetologia. 2016 Dec;59(12):2674-2685
pubmed: 27677765
Mol Cells. 2019 Nov 30;42(11):810-819
pubmed: 31707778
Nat Med. 2005 Mar;11(3):284-90
pubmed: 15711558
J Cell Sci. 2011 Nov 15;124(Pt 22):3811-21
pubmed: 22114304
FASEB J. 2017 Feb;31(2):469-481
pubmed: 27623929
Nat Med. 2012 Aug;18(8):1232-8
pubmed: 22820645
Sci Rep. 2018 Oct 5;8(1):14881
pubmed: 30291258

Auteurs

Hyun-Ju Kim (HJ)

Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute, BK21 PLUS KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu 41944, Korea.

Dong-Kyo Lee (DK)

Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute, BK21 PLUS KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu 41944, Korea.

Xian Jin (X)

Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute, BK21 PLUS KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu 41944, Korea.

Xiangguo Che (X)

Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute, BK21 PLUS KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu 41944, Korea.

Je-Yong Choi (JY)

Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute, BK21 PLUS KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu 41944, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH